Why the Current Definition Falls Short
In the latest issue of Psychiatric Times, Dr. Walter Paganin argues that the term „treatment‑resistant depression” (TRD) is misleading. He proposes the new label „difficult‑to‑treat depression” (DTD) to better reflect the complex realities clinicians face. The article was published on October 9, 2026, and draws on recent research and clinical experience.
Wellness insights
What Counselling in Two Different Countries Taught Me: Hansel Wong on Connection, Curiosity, and Culture
Dr. LaNail Plummer Shares Insights on Starting Therapy
GH001 Shows Rapid Relief for Postpartum Depression in Early Trial
Coping with a Breast Cancer Diagnosis: How to Support Your Loved OneThe core of Dr. Paganin’s argument is that TRD definitions vary widely, leading to inconsistent diagnoses. Many patients labeled as TRD actually have „pseudo‑resistance” caused by factors such as insufficient medication doses, short trial periods, poor adherence, or co‑existing medical conditions. By adopting DTD, clinicians can focus on individualized treatment plans that address these underlying issues.
Dr. Paganin notes that the traditional TRD model assumes a linear path: try one medication, switch if it fails, and so on. In reality, patients often receive subtherapeutic doses or brief treatment courses that do not allow a full assessment of efficacy. Additionally, comorbid anxiety, chronic pain, or substance use can mask or mimic depression, complicating the picture. These confounding variables create a false sense of resistance that can discourage both patients and providers from pursuing alternative therapies.
Can „Difficult‑to‑Treat” Improve Outcomes?
The new DTD framework encourages a systematic evaluation of each patient’s unique circumstances. It calls for thorough medication titration, adequate duration of trials, and close monitoring of adherence. When these steps are followed, many patients who were previously deemed TRD respond to treatment, reducing the stigma and frustration associated with the label.
The shift to DTD is not merely semantic. Dr. Paganin cites a multicenter study that found a 30% increase in remission rates when clinicians applied the DTD criteria. By distinguishing true pharmacoresistance from pseudo‑resistance, treatment teams can allocate resources more efficiently. They can prioritize evidence‑based interventions such as psychotherapy, neuromodulation, or novel pharmacotherapies for those who truly need them, while avoiding unnecessary medication escalation for others.
Furthermore, the DTD model aligns with precision medicine principles. It encourages the use of biomarkers, genetic testing, and patient‑reported outcomes to tailor treatments. This individualized approach may shorten the trial‑and‑error cycle and improve patient engagement. Patients who feel heard and understood are more likely to adhere to their treatment plans, leading to better long‑term outcomes.
How Will Clinicians Implement the New Model?
Implementing DTD requires changes at multiple levels. First, professional societies must update guidelines to reflect the new terminology and criteria. Second, training programs should emphasize comprehensive assessment techniques, including medication adherence checks and comorbidity screening. Third, electronic health records can incorporate decision‑support tools that flag potential pseudo‑resistance factors.
Pediatric and geriatric populations, often underrepresented in research, may benefit most from this approach. For example, older adults with polypharmacy issues may be misclassified as TRD due to drug interactions that reduce antidepressant efficacy. By recognizing these nuances, clinicians can adjust regimens or consider non‑pharmacologic options.
The future of depression treatment hinges on accurate diagnosis and personalized care. By moving away from the outdated TRD label and embracing DTD, the field can reduce misdiagnosis, improve patient outcomes, and foster a more compassionate therapeutic environment.
Frequently Asked Questions
What distinguishes difficult‑to‑treat depression from treatment‑resistant depression? DTD focuses on true pharmacologic resistance after adequate dosing, duration, and adherence, whereas TRD often includes cases of pseudo‑resistance caused by external factors.
Will the new terminology change insurance coverage? Insurance policies may need to adapt, but the DTD framework can help justify alternative therapies when standard treatments fail, potentially improving coverage decisions.
How can patients advocate for a DTD assessment? Patients should request a thorough medication review, ask about adherence support, and discuss any comorbid conditions that might affect treatment response.
